Mayo Clinic Center for Individualized Medicine
Division of Mayo Clinic
Latest From Mayo Clinic Center for Individualized Medicine
Actavis continues filling out its portfolio by acquiring Durata, but leaves room for other transformational deals. Impax moves strongly into generics and adds an FDA-licensed manufacturing site in buying three companies under the Tower Holdings umbrella.
The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.